Passage Bio Stock News

PHILADELPHIA, Jan. 03, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (

Passage Bio Inc (PASG) shares closed today at 1.0% above its 52 week low of $6.30, giving the company a market cap of $346M. The stock is currently down 75.0% year-to-date, down 76.7% over the past 12 months, and down 71.2% over the past five years. This week, the Dow Jones Industrial Average rose 2.6%, and the S&P 500 rose 3.0%. Trading Activity Trading volume this week was 26.7% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.2. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 148.3% The company's stock price performance over the past 12 months lags the peer average by 145.9% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Independent Data Monitoring Committee recommends proceeding with two additional planned patient cohorts, which are now being recruited in parallel Positive safety profile, including no serious adverse events, no complications related to intra-cisterna magna injection and no evidence of dorsal root ganglion toxicity Intra-cisterna magna delivery resulted in substantial increases in beta-galactosidase enzyme activity observed in both cerebrospinal fluid and serum Additional data to be shared in late-breaker presentation at the 18th Annual WORLD Symposium , February 11, 2022 Management to host a conference call and webcast today at 8 a.m. ET PHILADELPHIA, Dec. 17, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG ), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, today announced that the Independent Data Monitoring Committee (IDMC) recommended proceeding to additional planned cohorts in the Imagine-1 clinical study.

PHILADELPHIA, Dec. 08, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system disorders (CNS), today announced the expansion of its pipeline and provided a progress update on its three clinical programs.

Passage Bio, Inc. (NASDAQ:PASG) has been given a consensus rating of Buy by the ten research firms that are presently covering the stock, MarketBeat Ratings reports. Three investment analysts have rated the stock with a hold recommendation and seven have issued a buy recommendation on the company. The average 1-year price objective among brokerages that []

Charles Schwab Investment Management Inc. lifted its position in shares of Passage Bio, Inc. (NASDAQ:PASG) by 11.5% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 197,014 shares of the companys stock after buying an additional 20,326 shares during the quarter. Charles Schwab Investment []

Passage Bio, Inc. (NASDAQ:PASG) has been given an average rating of Buy by the ten research firms that are currently covering the company, MarketBeat Ratings reports. Three analysts have rated the stock with a hold recommendation and seven have given a buy recommendation to the company. The average 1 year target price among analysts that []

Cubist Systematic Strategies LLC grew its holdings in Passage Bio, Inc. (NASDAQ:PASG) by 302.9% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 43,348 shares of the companys stock after purchasing an additional 32,589 shares during the quarter. Cubist Systematic Strategies LLCs holdings in Passage []

PHILADELPHIA, Nov. 19, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, today announced it has granted an inducement award to a new employee.

Walleye Trading LLC bought a new stake in Passage Bio, Inc. (NASDAQ:PASG) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 24,400 shares of the companys stock, valued at approximately $323,000. Several other large investors also recently added to or reduced []

Passage Bio, Inc. (PASG) CEO Bruce Goldsmith on Q3 2021 Results - Earnings Call Transcript

PHILADELPHIA, Sept. 27, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders

PHILADELPHIA, Sept. 17, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system

PHILADELPHIA, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system

PHILADELPHIA, Aug. 27, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (